Search Results
The HemOnc Pulse Live at ASH: John DiPersio, MD, PhD, on Challenges, Role of HSCT in AML
The HemOnc Pulse Live at ASH: Jeffrey Lancet, MD, on Targeted Therapies for AML
Prognosis and Standard Treatment for AML-MRC
Leveraging Genomics, Cell Therapy and Gene Therapy to Cure Blood Cancers with Dr. John DiPersio ’73
John DiPersio, MD, PhD, explains what blood cancers are
LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates
John DiPersio, MD, PhD, explains stem cell & bone marrow transplants
ASH CAR-T and gene editing highlights
What are the possible side effects of immune therapies for acute myeloid leukemia?
Advancements in MCL treatment
JAK Inhibitors Targeting Hepcidin Pathway | Ravi Vij, MD, MBA | ASCO22 Leukemia Updates
